Aug 7 |
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
|
Jun 18 |
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
|
Jun 17 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
|
May 21 |
Inhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)
|
May 20 |
Inhibikase Therapeutics prices its direct offering, warrant inducement
|
May 20 |
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
|
May 18 |
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
|
May 16 |
Inhibikase Therapeutics GAAP EPS of -$0.73
|
May 16 |
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
|
May 15 |
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
|